T

Travere Therapeutics
D

TVTX

21.970
USD
-1.57
(-6.67%)
مغلق
حجم التداول
135,286
الربح لكل سهم
-1
العائد الربحي
-
P/E
-5
حجم السوق
1,912,143,637
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AGEN
    -0.11500
    (-3.34%)
    3.33000 USD
    B
    BCRX
    -0.17000
    (-1.81%)
    9.20000 USD
    C
    CRBP
    -0.09000
    (-1.09%)
    8.20000 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    J
    JAZZ
    -0.640
    (-0.47%)
    136.050 USD
    K
    KALA
    -0.16000
    (-2.33%)
    6.71000 USD
    NVS
    NVS
    2.100
    (1.96%)
    109.370 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    المزيد
الأخبار
المقالات

العنوان: Travere Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.